INTRODUCTION
Regulatory T (Treg) cells play a pivotal role in the maintenance of peripheral immunological tolerance and control of immune responses toward pathogens and tumors. In 1995, naturally occurring Treg cells were identified as a subpopulation within the CD4
1

CD25
1 T-cell population. 1 At that time, immunologists were skeptical of the suppressive nature of any T cells harboring this phenotype, as CD25 is highly expressed on activated effector T cells. Since then, scientists have made substantial progress in understanding their immune-suppressive function, and have resolved earlier problems of discriminating between the CD25 1 population of effector T cells and CD25 high -expressing Treg cells. [2] [3] [4] [5] In 2003, the forkhead box transcription factor FOXP3 was identified as a new specific marker of Treg cells, and its expression was found necessary and sufficient for their suppressive activity. [6] [7] [8] Scurfy mice, which lack Foxp3, would develop severe lymphoproliferative autoimmune disease attributed to the lack of an immune-suppressive component in the immune system. 9 Similar to mice, mutations in the Foxp3 gene of humans also leads to autoimmune disorder, a life-threatening disease called immune dysregulation, polyendocrinopathy and enteropathy, X-linked syndrome. 10 The identification of FOXP3 as a specific transcription factor for Treg cells has substantially progressed research on the development, differentiation and suppressive function of Treg cells.
In this review, we will summarize the latest findings on the heterogeneity, stability and plasticity of Treg cells, provide an overall understanding that how Tregs cells mediate their suppressive function and detail the underlying mechanisms of the molecular regulation of Treg cells. Further, we will show the relationship between Treg cells and physiological diseases, and relate these to relevant clinical trials to illuminate the possibility of using Treg cells to treat immune system disorders and other human diseases.
HETEROGENEITY OF TREG CELLS
Treg cells are a heterogeneous population with respect to their origin of development, functional activity and activation status. Treg cells are generally categorized into two groups: thymus-derived Treg (tTreg) cells and peripherally derived Treg (pTreg) cells, 2-5 also known as natural Tregs and induced Tregs, respectively. Both of the above Treg subsets are essential in maintaining immune homeostasis; however, further research has indicated that within these two subsets lie further heterogeneity relating to both phenotype and function.
Both the transcription factors Helios and the cell surface glycoprotein neuropilin-1 could be used to distinguish tTreg from pTreg cells. Helios and neuropilin-1 are usually highly expressed by tTreg cells but poorly expressed by pTreg cells; however, pTreg cells may upregulate expression of both these factors depending on local inflammatory conditions or the type of antigen-presenting cells and activation signals that are present. [11] [12] [13] Treg cells are a stable lineage with minimal capacity to dedifferentiate and convert into Teff cells, whereas CD25 low Treg cells may lose FOXP3 expression and convert into Th cells under certain conditions. 14 DNA methylation experiments have revealed that the Foxp3 promoter and conserved non-coding DNA sequence 2 (CNS2) region are highly 
FOXP3
low non-Treg cells have no immunosuppressive activity and express the proinflammatory cytokines IL-17, IL-2 and interferon-c (IFN-c). 19, 20 There is also substantial data that suggest how [21] [22] [23] Additionally, Jinfang Zhu and colleagues confirmed that Tbet Treg cells were able to convert into GATA3
1 Treg cells, and vice versa, which suggests that Th subset-specific reprogramming is a dynamic process. 24 
STABILITY AND PLASTICITY OF FOXP3
1 TREG CELLS The topic of Treg cell lineage stability and plasticity has been controversial for many years. Previously, scientists have found that some FOXP3 1 T cells may lose FOXP3 expression and acquire effector Th cell function under certain conditions. 25, 26 Purified FOXP3 1 T cells from Foxp3-reporter mice were found to lose FOXP3 expression and acquire the ability to produce Th cytokines when cultured in inflammatory conditions in vitro. Also, adoptive transfer of FOXP3 1 T cells were found instable, where approximately 50% of the donor cells became FOXP3 2 T cells, and converted into IFN-c-, IL-2-and IL-17-producing cells. 27 Former FOXP3 1 T cells (exFOXP3 1 T cells), were also found particularly increased in inflamed gut-associated tissues. [27] [28] [29] Bluestone and colleagues performed a fate mapping study with Foxp3-GFP-Cre BAC transgenic mice to trace the stability of FOXP3
1 T cells and found that 10%-20% of FOXP3
1 Treg cells lose FOXP3 expression and exhibit inflammatory Th cell phenotypes with the ability to secrete IFN-c and IL-17. 30 On the molecular level, we have identified how the stress-activated Stub1-Hsp70 complex plays a critical role in the degradation of FOXP3 and promotion of Treg cell conversion into Th1-like cells. 31 One possible reason for the divergent findings on the plasticity of Treg cells and the stability of the transcription factor FOXP3 is because of the mice model differences, including different intensities of reporter gene expression and distinct strengths of TCR and inflammatory signals under physiological conditions. These findings also suggest that the gene of Foxp3 transcription and the stability of its encoding protein are complicated and tightly modulated in vivo and in vitro, and how the process may involve an enormous diversity of epigenetic modifications and post-translational modifications that associate with the immunosuppressive activity of FOXP3 1 Treg cells.
MECHANISMS UNDERLYING THE SUPPRESSIVE FUNCTION OF FOXP3
1 TREG CELLS Multiple potential mechanisms have been identified for Treg suppressive function on the proliferation and activation of Teff cells in vitro and in vivo. These could be grouped into three different modes: suppression mediated by cell-cell contact, cytokine secretion and metabolic disruption.
The suppressive function of Treg cells may facilitate through their interaction with dendritic cells (DCs) or Teff cells directly. The co-stimulatory molecule CTLA4 is highly expressed on the surface of Treg cells and interacts with CD80 and CD86 ligands expressed on the surface of DCs. This interaction results in the upregulation and secretion of indoleamine 2, 3-dioxygenase by DC that then delivers a negative signal to Teff cells. 38 The suppressive function of Treg cells could also occurs through disruption of target cell metabolism. Treg cells highly express the IL-2 receptor a-chain on their cell surface, which facilitates high consumption of IL-2. Since IL-2 is also critical for the proliferation and activation of Teff cells, Treg cells may suppress the growth of Teff cells through IL-2 deprivation.
48,49
An additional mechanism is the expression of CD39 and CD73 on the surface of Treg cells, which could hydrolyze ATP or ADP, to cAMP, followed by inhibition of Teff cell function or DC maturation.
50-52
MOLECULAR MECHANISMS UNDERLYING THE FUNCTIONAL REGULATION OF FOXP3
1 TREG CELLS As a master regulator of Treg cells development, differentiation and immunosuppressive function, the expression level of the transcription factor FOXP3 is critical for maintaining immune homeostasis. 20 Foxp3 transcription can be regulated on the epigenetic level, while FOXP3 protein stability may be controlled by post-translational modification.
31,53-60 FOXP3 forms part of a large protein complex that regulates the expression of hallmark genes associated with Treg cell phenotype. [61] [62] [63] [64] The genomic region of the Foxp3 locus has several conserved non-coding sequences (CNS1, CNS2 and CNS3) that play different roles in the regulation of Foxp3 transcription. CNS1 contains binding sites for NFAT and AP-1 and is essential for peripheral, but not thymic, induction of FOXP3 expression. 16, 65 The binding of a RUNX1-CBF-b complex (runtrelated transcription factor 1-core-binding factor subunit-b complex) to CNS2 was shown to be crucial for sustaining a high and stable level of FOXP3 expression in Treg cells. 66 TCR stimulation activates the NF-kB family member REL for binding to CNS3, and is required for opening the Foxp3 promoter/enhancer region to promote FOXP3 expression. [67] [68] [69] Using CNS region-specific deficient mice, all the above findings were corroborated by Zheng and colleagues. 16 Additionally, it was also found that a conserved CpG island in the CNS2 region is hypomethylated in natural Treg cells, and hypermethylated in conventional CD4
1 T cells. The methylation status of the highly conserved CpG island, also referred to as the Treg-specific demethylated region, determines FOXP3 expression level and the stability of Treg cells. [70] [71] [72] The post-translational modification of proteins is critical for the regulation of protein localization, stability and functional activity. The transcription factor FOXP3 contains several functional domains: a proline-rich domain is necessary for transcriptional activity; zinc finger and leucine zipper domains critical for protein-protein interaction; and a forkhead domain that is responsible for DNA binding. Acetylation, ubiquitination and phosphorylation of FOXP3 and the crosstalk between different modifications of FOXP3 have been studied comprehensively (Figure 1) . The crystal structure of the NFAT1-FOXP3-DNA complex was resolved and the critical residues in FOXP3 that are responsible for its interaction with NFAT1 or DNA have been identified. 73 The identification of posttranslational modification sites may reveal those that are responsible for FOXP3 functional activity.
FOXP3 was first identified as an acetylated protein in human primary Treg cells. 53 TGF-b-mediated stimulation can increase FOXP3 acetylation and enhance FOXP3 association to chromatin. 74 Subsequently, FOXP3 was also found to undergo ubiquitination and the that ubiquitination would lead to its degradation. 31, 55 Since both ubiquitination and acetylation are restricted to lysine residues, acetylation may compete with poly-ubiquitination to stabilize FOXP3. 57 Two acetyltransferases, Tip60 and p300, have been reported as enzymes that are responsible for FOXP3 acetylation. The histone acetyltransferase Tip60 could be recruited to the repressor domain of FOXP3 and regulate FOXP3-mediated suppression on IL-2 expression.
53 p300 could also interact with FOXP3 and acetylate FOXP3 directly, and ectopic expression of p300 may strengthen FOXP3 stability. 57 In vivo data also confirmed that a p300 specific inhibitor could decrease FOXP3 acetylation and Treg cell activity in mice. 75 On the other hand, two lysine deacetylases, HDAC9 and SIRT1, can associate to FOXP3, and downregulates FOXP3 acetylation level and Treg activity, where knockdown of HDAC9 or SIRT1 has been shown to enhance Treg suppressive function in vitro.
76,77
Proteins with Lysine-48 (K48)-linked poly-ubiquitination may undergo proteasome-mediated degradation. 78 Recently, we demonstrated that proinflammatory cytokines and lipopolysaccharide could induce E3 ubiquitin ligase STUB1 expression and promote FOXP3 poly-ubiquitination and degradation in an Hsp70-dependent manner. Additionally, overexpression of STUB1 in Treg cells decreased their suppressive activity on the proliferation of Teff cells in vivo and in vitro, and induced a Th1-like phenotype, whereas knockdown of STUB1 expression in Treg cells enhanced their immunosuppressive activity. 31 Consistent with our findings, Loosdregt and colleagues demonstrated that the deubiquitinase USP7 acted oppositely to STUB1. The researchers found that USP7 interacted with FOXP3 in the nuclei and highly expressed in Treg cells. Ectopic expression of USP7 decreased FOXP3 polyubiquitination and increased its stability. Knockdown of USP7 expression or treatment with USP7 inhibitor decreased endogenous FOXP3 expression in Treg cells and reduced their immunosuppressive activity in vitro. Further, adoptive transfer of USP7 knockdown or USP7 inhibitor-treated Treg cells have reduced function in resolving induced colitis in mice. 55 Phosphorylation is the most common studied post-translational modification of proteins. 79 It has been reported that phosphorylation at Ser418 in the C-terminal DNA binding domain of FOXP3 positively regulates its DNA binding activity and transcriptional regulation that affects Treg cell suppressive function. TNF-a-induced protein phosphatase 1 (PP1) expression specifically dephosphorylates FOXP3 at Ser418 in Treg cells from rheumatoid arthritis patients, leading to Treg cell loss of its immunosuppressive function. Moreover, TNF-ainduced Treg dysfunction also increases numbers of IL-17 1 and IFN-c 1 CD4 1 T cells within inflamed synovia in rheumatoid arthritis. 60 Since the phosphorylation of FOXP3 at the Ser418 site is so critical for its activity regulation, further study is required in order to identify which kinase(s) are responsible. We have identified that PIM1 kinase phosphorylates FOXP3 and negatively regulates FOXP3 activity. 54 PIM1 is highly expressed in fresh isolated Treg cells and can specifically phosphorylate human FOXP3 at Ser422, which is not present in its murine equivalent. This leads to the downregulation of DNA binding and Treg suppressive function on the proliferation of Teff cells. In addition, our data indicates that FOXP3 phosphorylation at Ser422, mediated by PIM1, is sensitive to phosphoserine mimetic mutation (S418D), which suggests the existence of crosstalk between phosphor-Ser418 and phosphor-Ser422 of FOXP3. We have also identified that all the PP1 phosphatase family members, PPP1CA, PPP1CB and PPP1CC, could dephosphorylate FOXP3 at Ser422, while PPP1CA plays a role in phosphor-Ser418 dephosphorylation, suggesting that PP1 plays a flexible role in modulating Treg immunosuppressive activity to prevent unnecessary activation or repression (Li ZY and Li B, unpubl. data). It has also been reported that cyclin-dependent kinase 2 could interact and phosphorylate FOXP3 at its repressor domain and negatively regulate the stability and activity of FOXP3. 59 Lymphocytespecific protein kinase could interact and phosphorylate FOXP3 at Tyr-342 in cancer cells, and this phosphorylation is positively related with its ability to suppress gene expression in cancer cells. 1 Treg cells to prevent graft-versus-host disease (GVHD) after organ transplantation in cancer patients, and their results showed the reduction of acute GVHD or no chronic GVHD development. [81] [82] [83] On the other hand, a clinical trial has been launched to test whether Treg-depleted donor lymphocyte infusion improves graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation. 84 Their results indicated that donor lymphocyte infusion is a safe approach to induce acute graft-versus- Figure 1 Identified enzymes that are responsible for the post-translational modifications of FOXP3 and their corresponding modified residues in human FOXP3. Acetylation of FOXP3 at K263 and K268 by the acetyltransferase p300 stabilizes FOXP3 and promote its activity, while SIRT1 modulates the reciprocal modification. The E3 ligase STUB1 promotes the ubiquitination of FOXP3 at its leucine-zipper domain (K227, K250, K252, K263 and K268) and leads to its degradation, while the deubiquitinase USP7 prevents the ubiquitination process and stabilizes FOXP3. Acetylation and ubiquitination may compete for the same lysine residues in the leucine-zipper domain of FOXP3 to affect its stability and activity. FOXP3 is highly phosphorylated at Ser418 and dephosphorylation at the residue mediated by the phosphotase PP1 downregulates its repressive activity; The kinase PIM1 phosphorylates FOXP3 at Ser422 and negatively regulates FOXP3 activity, while the phosphatase PP1 works oppositely. Furthermore, phosphorylation at Ser418 prevents PIM1-mediated phosphorylation at Ser422. CDK2 phosphorylates FOXP3 at Ser88, Thr144 and Thr175 and promotes FOXP3 degradation. LCK phosphorylates FOXP3 at Tyr342 and enhances the repressive activity of FOXP3. CDK2, cyclindependent kinase 2; LCK, lymphocyte-specific protein kinase; PP1, protein phosphatase 1.
tumor effects in alloreactivity-resistant patients. In addition, other ongoing studies also infuse Treg-depleted donor lymphocytes to treat patients with relapsed hematological malignancies or in vivo strategies to decrease Treg cells with chemical reagents to activate tumor-specific immune responses in patients with advanced hepatocellular carcinoma. High doses of cyclophosphamide and sirolimus have been successfully used to prevent GVHD and have been shown to enhance the activity of Treg cells. [85] [86] [87] Although early studies have suggested a negative effect of cyclophosphamide on Treg cells, the role of Treg cells in the cyclophosphamide GVHD prophylactic effect, is essential. In the xenogenic GVHD mouse model, Kanakry and colleagues proved that when peripheral blood mononuclear cell grafts were depleted of Tregs, the humanized mice had severe GVHD scores and died earlier, and suggested the requirement of Treg cells for the optimal effect of cyclophosphamide. 88 Sirolimus, also named as rapamycin, preferentially inhibits effector T cells and results in the relative expansion of natural Treg cells. 89 Peccatori and colleagues showed how sirolimus-based GVHD prophylaxis facilitates the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors, which is a promising therapeutic option for high risk hematological malignancies. 87 In addition to above mentioned clinical trials, cyclophosphamide or sirolimus plus other immunosuppressive drugs, such as tacrolimus and ustekinumab, or the addition of low doses of IL-2 and a demethylating agent such as azacitidine to promote and stabilize the FOXP3 expression in Treg cells, are also under clinical testing. Successful ex vivo expansion of natural Treg cells or induction of induced Treg cells is critical for adoptive Treg cell infusion therapy of GVHD or autoimmune diseases. Thus, the identification of optimal reagents for enriched Treg cell preparation is extremely important. All-trans retinoic acid, the active derivative of vitamin A, could be used to efficiently convert naive CD4
PERSPECTIVE AND IMPLICATIONS
1 T cells to FOXP3-expressing highly suppressive induced Treg cells in the presence of TGF-b 90 and sustain the stability and function of natural Treg cells even during inflammation. 91, 92 As mentioned previously, rapamycin facilitates the expansion of functional CD4
1 CD25 1 FOXP3 1 Treg cells, but depletes Teff cells, and so it could be a useful tool to expand highly purified Treg cells for cellular immunotherapy.
To obtain highly stable and active ex vitro expanded Treg cells, we also propose that the study of how Treg cell activity is regulated via the post-translational modification of FOXP3, such as phosphorylation, ubiquitination and acetylation, may prove to be critical for manipulating Treg activity on the therapeutic level, which may positively or negatively regulate Treg cell function through modifying FOXP3 (Figure 2) . A PIM1-specific inhibitor could potentially be used to enhance the immunosuppressive activity of Treg cells through downregulating the phosphorylation of FOXP3-Ser422 during ex vivo preparation of Treg cells, 54 while PP1-specific inhibitor may work reversely and weaken the immunosuppressive activity of Treg cells; 60 STUB1-specific inhibitors, may stabilize Treg cells through preventing FOXP3 ubiquitination and degradation, whereas USP7-specific inhibitor treated Treg cells may lose their stability through promoting the process; 31, 55 SIRT1/HDAC9 inhibitors would enhance the activity of Treg cells through promoting FOXP3 acetylation and facilitating its stability or activity upregulation, while P300/TIP60 inhibitors may abolish the process and promote FOXP3 degradation mediated by FOXP3 ubiquitination. 53, 57, 75, 76 Along with the accumulation of our knowledge on the molecular mechanism of Treg immunosuppressive activity, we expect that in the next few years, increasingly safe and effective compounds, which could aid the ex vivo expansion of Treg cells by helping to maintain their stable function in vivo, will be identified and advance into clinical trials for the treatment of autoimmune diseases and other inflammatory diseases. 
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